Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Parkinson Disease in United States

252 results

Sort By:

Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

Study ID: NCT07348250
Start Date: 2025-12-08
End Date: 2026-12
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

22

Intervention / Treatment

[18F]MK-0947

Sponsor

Invicro

Source: clinicaltrials.gov

Share:
Add to list

10,000 Step Club: Community Walking Program for People with Parkinson's Disease

Study ID: NCT06605183
Start Date: 2024-09-11
End Date: 2025-12-20
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

60

Intervention / Treatment

Community walking program using Nordic walking poles

Sponsor

University of Nevada, Las Vegas

Source: clinicaltrials.gov

Share:
Add to list

Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease (Aim 2)

Study ID: NCT05070013
Start Date: 2021-11-18
End Date: 2026-06-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

Deep Brain Stimulation

Sponsor

University of Nebraska

Source: clinicaltrials.gov

Share:
Add to list

Neocortical Microarchitecture of Executive Function

Study ID: NCT06778135
Start Date: 2025-07-25
End Date: 2027-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

15

Intervention / Treatment

Temporary implatation of large-scale intracranial electrode.

brain electrode

Sponsor

University of Colorado, Denver

Source: clinicaltrials.gov

Share:
Add to list

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

Study ID: NCT06692920
Start Date: 2024-12-01
End Date: 2027-12-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

25

Intervention / Treatment

DBS stimulation

Sponsor

University of Minnesota

Source: clinicaltrials.gov

Share:
Add to list

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Study ID: NCT06623422
Start Date: 2024-10-21
End Date: 2038-01-26
Study Type

Interventional

Study Phase

Phase3

No. of Participants

680

Intervention / Treatment

Pembrolizumab

Cisplatin

Carboplatin

Pemetrexed

Gemcitabine

Paclitaxel

Intismeran autogene

Placebo

Sponsor

Merck Sharp & Dohme LLC

Source: clinicaltrials.gov

Share:
Add to list

Personalized Real-Time DBS and PD Mechanisms

Study ID: NCT06013956
Start Date: 2023-08-29
End Date: 2028-06-30
Study Type

Interventional

Study Phase

Phase4

No. of Participants

25

Intervention / Treatment

Neurostimulation

Carbidopa 25/Levodopa 100Mg Tab

Sponsor

David Escobar

Source: clinicaltrials.gov

Share:
Add to list

Gait Analysis in Neurological Disease

Study ID: NCT02994719
Start Date: 2016-03-01
End Date: 2026-06-20
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

120

Intervention / Treatment

Anti-Parkinson medication

Deep Brain Stimulation

Sponsor

Beth Israel Deaconess Medical Center

Source: clinicaltrials.gov

Share:
Add to list

Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503

Study ID: NCT06303921
Start Date: 2024-02-16
End Date: 2029-02
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

70

Intervention / Treatment

11C-M503 PET

Brain MRI

Amyloid PET

Neurological assessments

Sponsor

University of Pennsylvania

Source: clinicaltrials.gov

Share:
Add to list

Speech Learning and Speech Production in Parkinson's Disease

Study ID: NCT07403539
Start Date: 2026-01-27
End Date: 2027-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

50

Intervention / Treatment

Intensity learning

Intensity discrimination

Rate learning

Rate discrimination

Sponsor

State University of New York at Buffalo

Source: clinicaltrials.gov

Share:
Add to list